Blood test maker ViroGates' H1 revenue surges 173% on US orders
Blood test maker ViroGates' H1 revenue surges 173% on US orders
Overview
Denmark medical diagnostics maker's H1 revenue rose 173% yr/yr, driven by U.S. partner orders
Operating loss for H1 narrowed compared to last year
Outlook
ViroGates expects 2026 revenue of DKK 6.5-8 mln
Company sees 2026 EBIT of DKK -10 to -12 mln
Result Drivers
U.S. PARTNER STOCK BUILD-UP - Revenue growth mainly driven by deliveries to U.S. partner suPARbioTM under minimum order agreement
PARTNER SUPPORT ACTIVITIES - Co provided technical assistance and implementation support to suPARbioTM as it expanded U.S. testing capacity
Company press release: ID:nMFN5H848X
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
H1 Revenue |
| DKK 5.1 mln |
|
H1 Operating Expenses |
| -DKK 8.25 mln |
|
H1 Operating Profit |
| -DKK 3.90 mln |
|
Reuters Recommended Reads
Aug 20 - Denmark's BioPorto Q2 revenue falls 8% on recall, divestment
Aug 20 - Denmark's Evaxion Q2 net loss narrows on lower expenses
Aug 19 - UK's Oxford Nanopore H1 revenue rises on clinical, biopharma segements growth
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)